MedTrace Logo

Nitric Oxide Lung Diffusing Capacity in Systemic Sclerosis

NCT05505617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2026-04-22

No results posted yet for this study

Summary

To date, two devices to measure nitric oxide lung diffusing capacity (DLNO) are commercially available in Europe. Previous research has shown systematic between-device differences in lung diffusing capacity outcomes in healthy people (Radtke et al. ERJ Open Res. 2021 Sep 13;7(3)). The extent and magnitude of between-device differences in people with lung function impairment and ventilation inhomogeneities is unknown.

Conditions

Interventions

OTHER

Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.

Device: Jaeger Masterscreen TM (PFT Pro, Vyaire, Hoechberg, Germany) Device: HypAir Medisoft (Medisoft, Dinant, Belgium)

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • Holger Dressel

    lead OTHER

Principal Investigators

  • Holger Dressel, Prof · University of Zurich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2025-05-01
Completion
2026-03-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05505617 on ClinicalTrials.gov